{"id":6001,"date":"2023-09-01T08:06:49","date_gmt":"2023-09-01T08:06:49","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/realheart-selected-for-business-swedens-catalyst-programme\/"},"modified":"2023-09-01T08:06:49","modified_gmt":"2023-09-01T08:06:49","slug":"realheart-selected-for-business-swedens-catalyst-programme","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/realheart-selected-for-business-swedens-catalyst-programme\/","title":{"rendered":"Realheart selected for Business Sweden\u2019s Catalyst programme"},"content":{"rendered":"
Press release 2023-09-01<\/p>\n

Scandinavian Real Heart AB has been selected for Business Sweden's scale-up programme Catalyst, which aims to create international growth. In the program targeting Sweden\u2019s most innovative and promising companies, participants receive a customized project plan for market entry valued at 250,000 SEK and opportunities to build network in the market, among investors and other experts.<\/strong><\/div>\n

– Scandinavian Real Heart is one of Sweden\u2019s most exciting and innovative medtech companies. With Scandinavian Real Heart, Sweden has the opportunity to develop into a leading Life Science nation. We are proud that Scandinavian Real Heart chooses to work with Business Sweden and look forward to supporting the company in their global growth, says Jonas Thulin, program manager at Business Sweden.<\/span><\/span><\/span><\/span><\/p>\n

Through the program, Realheart receives for three months hands-on support in a selected market, as well as a customized market visit to increase understanding and to create networks.<\/span><\/span><\/span><\/span><\/p>\n

– The program gives us a springboard towards international growth with tailored commercialization support, advice and coaching in a chosen market. Having been selected also shows that the expert jury sees great potential for our artificial heart. Realheart will take advantage of this opportunity, says CEO Ina Laura Perkins.<\/span><\/span><\/span><\/span><\/p>\n

Realheart has been selected in the Asia\/Pacific program, a region where the company intends to work with partners and distributors for marketing and sales of its artificial heart. Through the program, the company will be able to intensify the work of identifying possible partners in the region and creating initial contacts with key parties. As part of this effort, CEO Ina Laura Perkins speaks at one of the world's largest cardiovascular disease congresses, the China Heart Congress at the turn of August\/September.<\/span><\/span><\/span><\/span><\/p>\n

The market in the Asia Pacific region is of size. The number of patients with heart failure is estimated in China to be around 12 million and in Southeast Asia to 9 million, which can be compared with 15 million in Europe and 6 million in the USA.<\/span><\/span><\/span><\/span><\/p>\n

\n

For more information please contact:<\/span><\/span><\/strong><\/span><\/p>\n

Ina Laura Perkins, CEO<\/span><\/span><\/p>\n

Phone: +46(0)70 406 49 21\u00a0<\/span><\/span><\/p>\n

E-mail: inalaura.perkins@realheart.se<\/span><\/span><\/p>\n

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se<\/a><\/p>\n<\/div>\n

\n

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart<\/em><\/span><\/span>\u00ae<\/span><\/span><\/span><\/em> TAH has a patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation.\u00a0<\/em><\/span><\/span>A unique concept in the medical technology world.<\/span><\/span><\/span><\/em><\/p>\n<\/div>\n